Indication example

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

[a fhir:ClinicalUseDefinition ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "example-indication"] ; # 
  fhir:contained ( [
     a fhir:Group ;
     fhir:id [ fhir:v "group" ] ;
     fhir:type [ fhir:v "person" ] ;
     fhir:membership [ fhir:v "definitional" ] ;
     fhir:characteristic ( [
       fhir:code [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/characteristic"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "age-range" ]
         ] )
       ] ;
       fhir:value [
         a fhir:Range ;
         fhir:low [
           fhir:value [ fhir:v "18"^^xsd:decimal ] ;
           fhir:unit [ fhir:v "a" ]
         ]
       ] ;
       fhir:exclude [ fhir:v "false"^^xsd:boolean ]
     ] )
  ] ) ; # 
  fhir:extension ( [
     fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ] ;
     fhir:value [ fhir:v "brr" ]
  ] ) ; # 
  fhir:type [ fhir:v "indication"] ; # 
  fhir:subject ( [
     fhir:reference [ fhir:v "MedicinalProductDefinition/example" ]
  ] ) ; # 
  fhir:indication [
     fhir:diseaseSymptomProcedure [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/indicationasdisease-symptom-procedure"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "Pulmonary-embolism-and-thrombosis-example-code" ]
         ] ) ;
         fhir:text [ fhir:v "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults." ]
       ]
     ] ;
     fhir:diseaseStatus [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/diseasestatus"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "Recurrent" ]
         ] )
       ]
     ] ;
     fhir:intendedEffect [
       fhir:concept [
         fhir:coding ( [
           fhir:system [ fhir:v "http://ema.europa.eu/example/intendedeffect"^^xsd:anyURI ] ;
           fhir:code [ fhir:v "PRYLX" ]
         ] )
       ]
     ]
  ] ; #   example product is indicated for Prevention of venous thromboembolic events  
  fhir:population ( [
     fhir:reference [ fhir:v "#group" ]
  ] )] . # 

# -------------------------------------------------------------------------------------